A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 112 participants.

Also called NCT03657095

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
Lung Biotechnology PBC (from the registry)
Registry
  • NCT NCT03657095
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Israel (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03657095. Non-randomized; no masking; primary purpose treatment. Start 2018-12-10 (actual); primary completion 2019-07-20 (actual). Results posted on 2020-09-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
Acronym
BEAT OLE
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Esuberaprost
Intervention (Drug)
Placebo
Lead sponsor
Lung Biotechnology PBC (class: industry)

Record details

Record id
cardio:ct-nct03657095
Content hash
5da27e69c82978baf483d25623fb838c983845fb7eaddbe9108d8d57a099129c